The need for a preoperative diagnosis due to gaps in the Bethesda cytological classification from fine needle aspiration (FNA) of thyroid nodules and the advent of molecular studies of these diseases have allowed the development of molecular tests for well-differentiated thyroid carcinoma, notably based on the identification of BRAF and RAS mutations as well as RET/PTC and PAX8/PPARy rearrangements [13, 14], among others such as Afirma GEC®, ThyGenX TEST®, and ThyroSeq TEST®, all without relevant application for multinodular goiter. The gene discussed is RET; the disease is thyroid nodule.